{
  "id": 6271638,
  "title": "STAT+: Inhibrx claims first win for long-sought immunotherapy target",
  "url": "https://urgent.news/2026/09/08/stat-inhibrx-claims-first-win-for-long-sought-immunotherapy-target",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-08T11:30:00.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/09/08/inhibrx-inbrx-106-ox40-immunotherapy-head-and-neck-cancer-hpv-positive/"
  },
  "original_language": "en",
  "account": null,
  "summary": "“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}